According to a new research, taking aspirin is associated with a 26 per cent increased risk of heart failure. The other factors associated with it are smoking, obesity, high blood pressure, high cholesterol, diabetes and cardiovascular disease.
The findings of this research have been published in the ESC Heart Failure Journal. “This is the first study to report that among individuals with a least one risk factor for heart failure, those taking aspirin were more likely to subsequently develop the condition than those not using the medication,” said study author Dr Blerim Mujaj of the University of Freiburg, Germany.
“While the findings require confirmation, they do indicate that the potential link between aspirin and heart failure needs to be clarified,” Mujaj added.
The influence of aspirin on heart failure is controversial. This study aimed to evaluate its relationship with heart failure incidence in people with and without heart disease and assessed whether using the drug is related to a new heart failure diagnosis in those at risk.
The analysis included 30,827 individuals at risk for developing heart failure who were enrolled from Western Europe and the US into the HOMAGE study.
“At-risk” was defined as one or more of the following: smoking, obesity, high blood pressure, high cholesterol, diabetes and cardiovascular disease. Participants were aged 40 years and above and free of heart failure at baseline. Aspirin use was recorded at enrolment and participants were classified as users or non-users. Participants were followed up for the first incidence of fatal or non-fatal heart failure requiring hospitalisation. The average age of participants was 67 years and 34 per cent were women.
At baseline, a total of 7,698 participants (25 per cent) were taking aspirin. During the 5.3-year follow-up, 1,330 participants had developed heart failure. The investigators assessed the association between aspirin use and incident heart failure after adjusting for sex, age, body mass index, smoking, alcohol use, blood pressure, heart rate, blood cholesterol, creatinine, hypertension, diabetes, cardiovascular disease, and treatment with renin-angiotensin-aldosterone-system inhibitors, calcium channel blockers, diuretics, beta-blockers and lipid-lowering drugs.
Taking aspirin was independently associated with a 26 per cent raised risk of a new heart failure diagnosis. To check the consistency of the results, the researchers repeated the analysis after matching aspirin users and non-users for heart failure risk factors. In this matched analysis, aspirin was associated with a 26 per cent raised risk of a new heart failure diagnosis. To check the results further, the analysis was repeated after excluding patients with a history of cardiovascular disease. In 22,690 participants (74 per cent) free of cardiovascular disease, aspirin use was associated with a 27 per cent increased risk of incident heart failure.
Dr Mujaj said, “This was the first large study to investigate the relationship between aspirin use and incident heart failure in individuals with and without heart disease and at least one risk factor. Aspirin is commonly used — in our study one in four participants were taking the medication. In this population, aspirin use was associated with incident heart failure, independent of other risk factors.”
He concluded, “Large multinational randomised trials in adults at risk for heart failure are needed to verify these results. Until then, our observations suggest that aspirin should be prescribed with caution in those with heart failure or with risk factors for the condition.”